Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience

David J Lubin, Caleb Tsetse, Mohammad S Khorasani, Massoud Allahyari, Mary McGrath, David J Lubin, Caleb Tsetse, Mohammad S Khorasani, Massoud Allahyari, Mary McGrath

Abstract

Well-differentiated thyroid carcinoma is predominantly a slow-growing malignancy, amendable to treatment, and has an excellent prognosis following thyroidectomy and radioiodine (RAI) therapy. However, patients who fail the initial RAI treatment attempt may require repeated RAI or other treatments and with this, comes an associated impact on patient quality of life. Therefore, the anticipation of patients in whom there is a higher risk of RAI failure may help in patient risk stratification and subsequent management. We conducted a retrospective review to determine the factors associated with initial RAI therapy failure in well-differentiated thyroid cancer patients. Using scikit-learn from Python, we implemented a machine-learning algorithm to determine the clinical patient factors associated with a higher likelihood of treatment resistance. We found that clinical factors such as tumor focality (P = 0.026) and lymph node invasion at surgical resection (P = 0.0135) were significantly associated with initial treatment failure following RAI. Elevated serum thyroglobulin (Tg) and Tg antibody levels following surgery but before RAI were also associated with treatment resistance (P < 0.0001 and P = 0.011 respectively). Less expected factors such as decreased time from surgery to RAI were also associated with treatment failure, however not to a statistically significant degree (P > 0.064). Clinical outcomes following RAI can be stratified by identifying factors that are associated with initial treatment failure. These findings can help restratify patients for RAI treatment and change patient management in certain cases. Such stratification will ultimately help to optimize successful treatment outcomes and improve patient quality of life.

Keywords: Machine learning; radioiodine ablation; restratification; thyroglobulin; thyroid cancer.

Conflict of interest statement

There are no conflicts of interest.

Copyright: © 2021 World Journal of Nuclear Medicine.

Figures

Figure 1
Figure 1
Relative risk of initial radioiodine treatment failure associated with specific patient clinical features. Whiskers denote the 95% confidence interval
Figure 2
Figure 2
The number of cases of initial radioiodine treatment failure (dark gray bars) and successful RAI treatment (light gray bars) following thyroidectomy. Number of cases of each clinical response are displayed according to the number of months between surgical resection and RAI treatment

References

    1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.
    1. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461–70.
    1. Mendoza ES, Lopez AA, Valdez VA, Cunanan EC, Matawaran BJ, Kho SA, et al. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital. J Endocrinol Invest. 2016;39:55–62.
    1. Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL. Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20:1728–35.
    1. Aschebrook-Kilfoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, Angelos P, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013;22:1252–9.
    1. Pedregosa, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine learning in python. JMLR. 2011;12:2825–30.
    1. Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D'Antonio A, et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2020 Jun 10; DOI:10.1007/s12020-020-02379-1, PMID: 32529282.
    1. Buitinck L, Louppe G, Blondel M, Pedregosa F, Mueller A, Grisel O, et al. API design for machine learning software: Experiences from the scikit-learn project, European Conference on Machine Learning and Principles and Practices of Knowledge Discovery in Databases. arXiv. 2013 arXiv:1309.0238v1.
    1. [Last Accessed on 2020 Dec 24]. Available from: .
    1. Cao CJ, Dou CY, Lian J, Luan ZS, Zhou W, Xie W, et al. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. Oncol Lett. 2018;15:8141–8.
    1. Ciarallo A, Rivera J. Radioactive iodine therapy in differentiated thyroid cancer: 2020 update. AJR Am J Roentgenol. 2020;215:285–91.
    1. Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D'Antonio A, et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2020 Jun 10; DOI:10.1007/s12020-020-02379-1, PMID: 32529282.
    1. Lo TE, Uy AT, Maningat PD. Well-differentiated thyroid cancer: The Philippine general hospital experience. Endocrinol Metab (Seoul) 2016;31:72–9.
    1. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;19:1043–8.

Source: PubMed

3
Předplatit